Nymox Pharmaceutical Corporation (NYM.SG)

1.7500 0.0000 (0.00%) As of 08:29PM CEST. Market open.

Nymox Pharmaceutical Corporation

Bay & Deveaux Streets
Nassau
Bahamas
800 936 9669
https://nymox.com

Sector(s): 
Industry: 
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Paul Averback DABP, M.D.	Founder, Chairman, CEO & President	612.76k	N/A	1951
Ms. Lin Dodd	QA and Compliance Manager	N/A	N/A	N/A
Mr. Patrick Doody	VP, General Counsel & Director	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

Corporate Governance

Nymox Pharmaceutical Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.